Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care

March 14, 2007 updated by: Wyeth is now a wholly owned subsidiary of Pfizer

Prospective Observational Study of Mylotarg (Gemtuzumab Ozogamicin) in Usual Care

This study is designed to assess the safety of Mylotarg therapy in routine practice.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment

500

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Arizona
      • Tucson, Arizona, United States, 85404
    • California
      • Berkely, California, United States, 94704
      • Burbank, California, United States, 91505
      • Concord, California, United States, 94520
      • Loma Linda, California, United States, 92354
      • Los Angeles, California, United States, 90095-1678
      • San Francisco, California, United States, 94143
      • Sylmar, California, United States, 91342
    • Colorado
      • Denver, Colorado, United States, 80218
    • Florida
      • Boynton Beach, Florida, United States, 33435
      • Plantation, Florida, United States, 33324
      • Stuart, Florida, United States, 34994
      • Tamarac, Florida, United States, 33321
    • Illinois
      • Chicago, Illinois, United States, 60637
      • Chicago, Illinois, United States, 60611
      • Chicago, Illinois, United States, 60612-3838
      • Chicago, Illinois, United States, 60612-7323
    • Indiana
      • Indianapolis, Indiana, United States, 46202
    • Iowa
      • Iowa City, Iowa, United States, 52242
    • Kentucky
      • Lexington, Kentucky, United States, 40536-0093
      • Louisville, Kentucky, United States, 40202
    • Louisiana
      • Shrevport, Louisiana, United States, 71130-3932
    • Michigan
      • Ann Arbor, Michigan, United States, 48109-0999
      • Grand Rapids, Michigan, United States, 49503
      • Kalamazoo, Michigan, United States, 49048
      • Kalamazoo, Michigan, United States, 49007-3731
    • Missouri
      • Columbia, Missouri, United States, 65203
      • St. Louis, Missouri, United States, 63141
    • New Jersey
      • Neptune, New Jersey, United States, 07754
    • New Mexico
      • Albuquerque, New Mexico, United States, 87109
    • New York
      • Bronx, New York, United States, 10466
      • Buffalo, New York, United States, 14263
      • New Hyde Park, New York, United States, 11040
      • New York, New York, United States, 10032
      • New York, New York, United States, 10019
      • Valhalla, New York, United States, 10595
    • North Carolina
      • Durham, North Carolina, United States, 27705
      • Winston-Salem, North Carolina, United States, 27106
    • North Dakota
      • Bismarck, North Dakota, United States, 58501
    • Ohio
      • Akron, Ohio, United States, 44302
      • Canton, Ohio, United States, 44718
      • Cincinnati, Ohio, United States, 45236
      • Cleveland, Ohio, United States, 44195
    • Oklahoma
      • Oklahoma City, Oklahoma, United States, 72112
    • Oregon
      • Portland, Oregon, United States, 97201
    • Pennsylvania
      • Hershey, Pennsylvania, United States, 17033-0850
      • Philadelphia, Pennsylvania, United States, 19104
      • Philadelphia, Pennsylvania, United States, 19107
      • Pittsburgh, Pennsylvania, United States, 15224
    • Tennessee
      • Memphis, Tennessee, United States, 38120
      • Nashville, Tennessee, United States, 37205
      • Nashville, Tennessee, United States, 37232-5505
    • Texas
      • Houston, Texas, United States, 77030
      • Temple, Texas, United States, 76508
    • Virginia
      • Arlington, Virginia, United States, 22205
      • Richmond, Virginia, United States, 23298-0157
    • West Virginia
      • Charleston, West Virginia, United States, 25304
      • Morgantown, West Virginia, United States, 26506-9162
    • Wisconsin
      • Appleton, Wisconsin, United States, 54911

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Treated by Mylotarg
  • Provide ICF

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2001

Study Registration Dates

First Submitted

September 8, 2005

First Submitted That Met QC Criteria

September 11, 2005

First Posted (ESTIMATE)

September 12, 2005

Study Record Updates

Last Update Posted (ESTIMATE)

March 15, 2007

Last Update Submitted That Met QC Criteria

March 14, 2007

Last Verified

March 1, 2007

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 0903X-100847

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe